Neuroblastoma Clinical Trials 2023

What are the top hospitals conducting neuroblastoma research?

When it comes to the fight against neuroblastoma, a rare and aggressive cancer that primarily affects children, several top hospitals across the United States are leading the charge in clinical trials. In Los Angeles, Children's Hospital Los Angeles takes center stage with an impressive 28 ongoing trials focused on neuroblastoma. This renowned institution has been at the forefront of research for this condition since recording its first trial in 1988. Similarly, Cincinnati Children's Hospital Medical Center also boasts 28 active neuroblastoma trials and carries an exceptional track record with a total of 86 completed studies since their first recorded trial in 1988.

Not to be outdone, Memorial Sloan Kettering Cancer Center in New York is making significant contributions as well. With 28 currently active neuroblastoma trials and a solid history of 55 previous studies conducted since initiating their inaugural trial in 1995, they remain dedicated to advancing our understanding and treatment options for this challenging disease.

Meanwhile, Children's Hospital Colorado located in Aurora has emerged as another key player with its commitment to finding innovative solutions through its ongoing participation in twenty-five active neuroblastoma trials while having conducted forty-seven overall studies starting from their initial investigation into these cases back in2000.With consistent pursuit towards medical progress within Kansas City area itself;Children’s Mercy Hospitals & Clinics have not only made valuable contribution by actively partaking25ongoing research projects specifically targeting Neuroblatstomatic conditions but also deserve appreciation for dedicating time to previous four decades long forty investigations covering numerous aspects pertaining such complex ailment ,starting from year2000 onwards

These esteemed hospitals represent hope for families affected by neuroblastoma and exemplify the tireless efforts undertaken by healthcare professionals nationwide. The collective endeavors of these institutions bring us closer to breakthroughs that will improve outcomes for patients battling this devastating disease. Through cutting-edge research and compassionate care, they champion advancements that hold promise for a brighter future in the fight against neuroblastoma.

Which are the best cities for neuroblastoma clinical trials?

When it comes to neuroblastoma clinical trials, several cities have emerged as key hubs for research and innovation. New York City leads the pack with 72 active trials, focusing on a range of treatments including Palbociclib, Selumetinib Sulfate, and others. Following closely behind are Saint Louis in Missouri with 64 ongoing studies exploring options like Palbociclib and Cyclophosphamide, and Orlando in Florida with 61 trials investigating similar interventions. Chicago in Illinois also boasts a significant presence with 53 active trials studying Temozolomide and Autologous Hematopoietic Stem Cell Transplantation among other potential therapies. Finally, Boston in Massachusetts. New York City leads the pack with 72 active trials, focusing on a range of treatments including Palbociclib, Selumetinib Sulfate, and others. Following closely behind are Saint Louis in Missouri with 64 ongoing studies exploring options like Palbociclib and Cyclophosphamide, and Orlando in Florida with 61 trials investigating similar interventions. Chicago in Illinois also boasts a significant presence with 53 active trials studying Temozolomide and Autologous Hematopoietic Stem Cell Transplantation among other potential therapies. Finally, Boston in Massachusetts rounds out the top five cities with 48 ongoing studies investigating treatments such as induction therapy, consolidation therapy, ASCT (autologous stem cell transplantation), and more. These cities offer individuals battling neuroblastoma access to cutting-edge clinical trials that give hope for improved outcomes through innovative approaches to treatment.

Which are the top treatments for neuroblastoma being explored in clinical trials?

Cutting-edge research in the fight against neuroblastoma has identified several promising treatments currently under exploration in clinical trials. Leading the pack is a pharmacological study, with four active trials and 16 all-time neuroblastoma trials since its initial listing in 2001. DFMO, another notable contender, shines brightly with three ongoing trials and six all-time neuroblastoma studies since its introduction in 2010. Also showing great potential is 131I-MIBG, which joins the race boasting two active and five all-time neuroblastoma trials following its first appearance on the scene in 2005. Rounding out this impressive lineup is nivolumab, gaining traction with two active and six all-time neuroblastoma trials after making waves upon its arrival in 2015. With each trial comes renewed hope for finding effective treatments for those facing this challenging disease.

What are the most recent clinical trials for neuroblastoma?

Recent clinical trials offer promising prospects for the treatment of neuroblastoma, a challenging pediatric cancerf neuroblastoma, a challenging pediatric cancer. One notable trial investigates the combination of ex vivo expanded allogeneic γδ T cells with dinutuximab, temozolomide, irinotecan, and zoledronate. In another study, researchers are exploring an innovative approach using anti-CD30 bispecific antibody-armed anti-CD3-activated autologous T-cells (CD30 biAb-AATC). These trials aim to evaluate their effectiveness in improving outcomes for patients with neuroblastoma. While still in early phases, these advancements hold great potential for enhancing therapeutic options and ultimately improving survival rates for those battling this aggressive disease.

What neuroblastoma clinical trials were recently completed?

A recent completion of a clinical trial for neuroblastoma involved the investigation of chemotherapy and was sponsored by AbbVie. This trial concluded in November 2017, providing valuable insights into the efficacy and safety of this treatment approach. The findings from this study contribute to our understanding of how chemotherapy can be utilized in combating neuroblastoma, offering potential avenues for improved patient outcomes.